The 
Introduction.
The use of gold compounds in the treatment of rheumatoid arthritis is well documented [1 3] . Given the clinical success of such compounds, it is not surprising that gold derivatives have also been examined for their potential anti-tumour activity. Among the most active species investigated was the bis chelated diphosphine gold(I) cation, [Au(dppe)2] + where dppe is Ph2PCH2CH2PPh2 [4, 5] ; this complex proved to be a potent cardiovascular toxin [6] . In this context the anti-tumour activity/cytotoxicity of a series of phosphinegold(I) thiolates have been investigated [7, 8] and we have reported the in vitro growth inhibitory activity of a series of phosphinegold(I) thionucleobases with the general formula [R3PAu(SR)], where R Et, Ph or c-hexyl, and SRH 2-mercaptobenzoic acid, 2-thiouracil, 6-mercaptopurine (6-MPH), or 6-thioguanine (6-TGH) [9] . These latter two thionucleobases are anticancer drugs that are used clinically in the treatment of leukaemia [10] . All of the gold complexes showed excellent growth inhibition activity against the L1210 murine leukaemia in vitro. The activity was generally 10 to 100-fold better than for cisplatin and carboplatin, the only other metal-containing anticancer drugs in routine clinical use. The development of resistance to these platinum agents is a significant clinical problem [11] increasing concentrations of albumin were present in the growth medium. Thus, further in vitro studies with these triphenylphosphinegold(I) thionucleobases will be necessary to assess their reactivity with biological solutions. In addition, it is important to determine the mechanism of action of these compounds in order to guide further development and testing.
